Health and Medicine
Apr. 10, 2020—Vanderbilt University Medical Center is leading a clinical trial to understand if a well-known drug used for malaria and rheumatologic conditions is safe and effective in treating hospitalized adults with COVID-19.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 9, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Apr. 8, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Apr. 8, 2020—Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease.
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Mar. 12, 2020—Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
Mar. 10, 2020—This is not the Jedi you're thinking of. This Jedi is a receptor that helps clear away dead neurons during development, and its loss changes the activity of dorsal root ganglia neurons, which could have implications for treating chronic pain.